This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Deedwania, P. C Articles by Schmieder, R. Search for Related Content PubMed PubMed Citation Articles by Deedwania, P. C Articles by Schmieder, R. Pubmed/NCBI databases Medline Plus Health Information Metabolic Syndrome Social Bookmarking                         What's this?

Angiotensin Receptor Blockers: Cardiovascular Protection in the Metabolic Syndrome

University of California at San Francisco, San Francisco, CA, USA, deed{at}fresno.ucsf.edu

Roland Schmieder

University of Erlangen-Nuremberg, Germany

It is well recognised that the metabolic syndrome, a constellation of risk factors including obesity, hypertension, insulin resistance and dyslipidaemia, is associated with an increased risk of cardiovascular complications and the development of Type 2 diabetes. Consequently, timely identification and management of all components of the metabolic syndrome is warranted. In particular, guidelines have emphasised the importance of targeting elevated blood pressure (BP) and dyslipidaemia as a method of reducing global cardiovascular risk.

Findings from the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial show that the angiotensin receptor blocker, valsartan, reduces cardiovascular events and the development of Type 2 diabetes in high-risk individuals. This profile is being further explored in the ongoing Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.

Given the potential advantages to patients and physicians of tackling more than one of the components of the metabolic syndrome, antihypertensive agents such as valsartan would appear to be an important addition to the management of vulnerable patients at high risk of cardiovascular events.

Key Words: Valsartan • Angiotensin receptor blockers • Hypertension • Metabolic syndrome

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 1 suppl, S12-S18 (2006)
DOI: 10.3317/jraas.2006.018


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. W. Brands and H. Labazi Role of Glomerular Filtration Rate in Controlling Blood Pressure Early in Diabetes Hypertension, August 1, 2008; 52(2): 188 - 194. [Full Text] [PDF]